Thibaud Damy

List of Publications by Year in descending order

109 papers	8,125 citations	94433 37 h-index	49909 87 g-index
111 all docs	111 docs citations	111 times ranked	5919 citing authors

#	Article	IF	Citations
1	Transthyretin cardiac amyloidosis in continental Western Europe: an insight through the Transthyretin Amyloidosis Outcomes Survey (THAOS). European Heart Journal, 2022, 43, 391-400.	2.2	105
2	Utilization of sacubitril/valsartan in patients with heart failure with reduced ejection fraction: real-world data from the ARIADNE registry. European Heart Journal Quality of Care & Clinical Outcomes, 2022, 8, 469-477.	4.0	9
3	Adaptive servo ventilation for sleep apnoea in heart failure: the FACE study 3-month data. Thorax, 2022, 77, 178-185.	5.6	20
4	Tafamidis and quality of life in people with transthyretin amyloid cardiomyopathy in the study ATTR-ACT: A plain language summary. Future Cardiology, 2022, 18, 165-172.	1.2	2
5	Prescription, Compliance, and Burden Associated with Salt-Restricted Diets in Heart Failure Patients: Results from the French National OFICSel Observatory. Nutrients, 2022, 14, 308.	4.1	4
6	Describing mode of death in three major cardiac amyloidosis subtypes to improve management and survival. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2022, 29, 79-91.	3.0	2
7	Prevalence and determinants of iron deficiency in cardiac amyloidosis. ESC Heart Failure, 2022, 9, 1314-1327.	3.1	4
8	Practical outpatient management of worsening chronic heart failure. European Journal of Heart Failure, 2022, 24, 750-761.	7.1	27
9	Characteristics and natural history of early-stage cardiac transthyretin amyloidosis. European Heart Journal, 2022, 43, 2622-2632.	2.2	27
10	Practical Guidance for Diagnosing and Treating Iron Deficiency in Patients with Heart Failure: Why, Who and How?. Journal of Clinical Medicine, 2022, 11, 2976.	2.4	5
11	Prognostic value of cardiopulmonary exercise testing in cardiac amyloidosis. European Journal of Heart Failure, 2021, 23, 231-239.	7.1	26
12	Epidemiological characteristics and therapeutic management of patients with chronic heart failure who use smartphones: Potential impact of a dedicated smartphone application (report from the) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 2	1.6	11
13	Natural history and impact of treatment with tafamidis on major cardiovascular outcomeâ€free survival time in a cohort of patients with transthyretin amyloidosis. European Journal of Heart Failure, 2021, 23, 264-274.	7.1	30
14	Efficacy and safety of tafamidis doses in the <scp>Tafamidis in Transthyretin Cardiomyopathy Clinical Trial</scp> (<scp>ATTRâ€ACT</scp>) and longâ€term extension study. European Journal of Heart Failure, 2021, 23, 277-285.	7.1	103
15	Impact of Tafamidis on Health-Related Quality of Life in Patients With Transthyretin Amyloid Cardiomyopathy (from the Tafamidis in Transthyretin Cardiomyopathy Clinical Trial). American Journal of Cardiology, 2021, 141, 98-105.	1.6	21
16	Efficacy of Tafamidis in Patients With Hereditary and Wild-Type Transthyretin Amyloid Cardiomyopathy. JACC: Heart Failure, 2021, 9, 115-123.	4.1	52
17	Prevalence and prognostic value of autonomic neuropathy assessed by SudoscanÂ® in transthyretin wildâ€type cardiac amyloidosis. ESC Heart Failure, 2021, 8, 1656-1665.	3.1	11
18	Reply to the letter regarding the article â€˜Efficacy and safety of tafamidis doses in the Tafamidis in Transthyretin Cardiomyopathy Clinical Trial (<scp>ATTRâ€ACT</scp>) and longâ€term extension studyâ€™. European Journal of Heart Failure, 2021, 23, 1057-1058.	7.1	1

#	Article	IF	Citations
19	Diagnosis and Treatment of Iron Deficiency in Heart Failure: OFICSel study by the French Heart Failure Working Group. ESC Heart Failure, 2021, 8, 1509-1521.	3.1	14
20	Severe Heart Failure Associated With Tachycardia-Induced Cardiomyopathy Due to Incessant Atrioventricular Re-Entrant Tachycardia. JACC: Case Reports, 2021, 3, 479-483.	0.6	1
21	The Impact of Patients With CardiacÂAmyloidosis in HFpEF Trials. JACC: Heart Failure, 2021, 9, 169-178.	4.1	39
22	Diagnosis and treatment of cardiac amyloidosis: a position statement of the ESC Working Group on Myocardial and Pericardial Diseases. European Heart Journal, 2021, 42, 1554-1568.	2.2	434
23	ATTR amyloidosis during the COVID-19 pandemic: insights from a global medical roundtable. Orphanet Journal of Rare Diseases, 2021, 16, 204.	2.7	11
24	Coronavirus disease vaccination in heart failure: No time to waste. Archives of Cardiovascular Diseases, 2021, 114, 434-438.	1.6	6
25	Expert consensus on the monitoring of transthyretin amyloid cardiomyopathy. European Journal of Heart Failure, 2021, 23, 895-905.	7.1	57
26	A simple core dataset and disease severity score for hereditary transthyretin (ATTRv) amyloidosis. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2021, 28, 189-198.	3.0	12
27	Hypertrophic cardiomyopathies requiring more monitoring for less atrial fibrillation-related complications: a clustering analysis based on the French registry on hypertrophic cardiomyopathy (REMY). Clinical Research in Cardiology, 2021, , 1.	3.3	0
28	Progress and challenges in the treatment of cardiac amyloidosis: a review of the literature. ESC Heart Failure, 2021, 8, 2380-2396.	3.1	29
29	First symptoms and health care pathways in hospitalized patients with acute heart failure: <scp>ICPS2</scp> survey. A report from the Heart Failure Working Group (GICC) of the French Society of Cardiology. Clinical Cardiology, 2021, 44, 1144-1150.	1.8	6
30	Frailty in Wild-Type Transthyretin Cardiac Amyloidosis: The Tip of the Iceberg. Journal of Clinical Medicine, 2021, 10, 3415.	2.4	8
31	Diagnostic Value of Extracellular Volume Quantification and Myocardial Perfusion Analysis at CT in Cardiac Amyloidosis. Radiology, 2021, 300, 326-335.	7.3	11
32	Dexamethasone is associated with early deaths in light chain amyloidosis patients with severe cardiac involvement. PLoS ONE, 2021, 16, e0257189.	2.5	12
33	Vaccination for Respiratory Infections in Patients with Heart Failure. Journal of Clinical Medicine, 2021, 10, 4311.	2.4	6
34	Prognostic Value of N-Terminal Pro-Brain Natriuretic Peptide and High-Sensitivity Troponin T Levels in the Natural History of Transthyretin Amyloid Cardiomyopathy and Their Evolution after Tafamidis Treatment. Journal of Clinical Medicine, 2021, 10, 4868.	2.4	9
35	Echocardiographic Patterns of Left Ventricular Diastolic Function in Cardiac Amyloidosis: An Updated Evaluation. Journal of Clinical Medicine, 2021, 10, 4888.	2.4	4
36	History of extracardiac/cardiac events in cardiac amyloidosis: prevalence and time from initial onset to diagnosis. ESC Heart Failure, 2021, 8, 5501-5512.	3.1	11

#	Article	IF	Citations
37	Assessing Cardiac Amyloidosis SubtypesÂby Unsupervised Phenotype Clustering Analysis. Journal of the American College of Cardiology, 2021, 78, 2177-2192.	2.8	11
38	Echocardiographic Evaluation of Left Ventricular Filling Pressure in Patients With Heart Failure With Preserved Ejection Fraction: Usefulness of Inferior Vena Cava Measurements and 2016 EACVI/ASE Recommendations. Journal of Cardiac Failure, 2020, 26, 507-514.	1.7	10
39	Aortic stenosis and amyloid heart disease: â€˜the 2A dangerous liaisonsâ€™. European Heart Journal, 2020, 41, 2815-2815.	2.2	0
40	Avoiding misdiagnosis: expert consensus recommendations for the suspicion and diagnosis of transthyretin amyloidosis for the general practitioner. BMC Family Practice, 2020, 21, 198.	2.9	60
41	Extracardiac soft tissue uptake, evidenced on early 99mTc-HMDP SPECT/CT, helps typing cardiac amyloidosis and demonstrates high prognostic value. European Journal of Nuclear Medicine and Molecular Imaging, 2020, 47, 2396-2406.	6.4	18
42	Deleterious effect of right ventricular pacing in patients with cardiac transthyretin amyloidosis: potential clinical benefit of cardiac resynchronization therapy. European Heart Journal - Case Reports, 2020, 4, 1-5.	0.6	1
43	Management of heart failure with reduced ejection fraction in Europe: design of the ARIADNE registry. ESC Heart Failure, 2020, 7, 727-736.	3.1	7
44	Cohort profile: FACE, prospective follow-up of chronic heart failure patients with sleep-disordered breathing indicated for adaptive servo ventilation. BMJ Open, 2020, 10, e038403.	1.9	10
45	Quantification of Myocardial Enhancement on Cine-MRI: Diagnostic Value in Cardiac Amyloidosis. Academic Radiology, 2019, 26, e98-e107.	2.5	3
46	Pharyngo-laryngeal involvement in systemic amyloidosis with cardiac involvement: a prospective observational study. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2019, 26, 216-224.	3.0	11
47	Extracorporeal membrane oxygenation support in acute circulatory failure: A plea for regulation and better organization. Archives of Cardiovascular Diseases, 2019, 112, 441-449.	1.6	6
48	Expert Consensus Recommendations for the Suspicion and Diagnosis of Transthyretin Cardiac Amyloidosis. Circulation: Heart Failure, 2019, 12, e006075.	3.9	312
49	Association between hearing loss and hereditary ATTR amyloidosis. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2019, 26, 234-242.	3.0	9
50	Causes and consequences of cardiac fibrosis in patients referred for surgical aortic valve replacement. ESC Heart Failure, 2019, 6, 649-657.	3.1	6
51	Renal Infarction and Its Consequences for Renal Function in Patients With Cardiac Amyloidosis. Mayo Clinic Proceedings, 2019, 94, 961-975.	3.0	5
52	Early diagnosis of ATTR amyloidosis through targeted follow-up of identified carriers ofTTRgene mutations*. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2019, 26, 3-9.	3.0	102
53	Aortic Stenosis and Cardiac Amyloidosis. Journal of the American College of Cardiology, 2019, 74, 2638-2651.	2.8	182
54	Left ventricular assessment in patients with systemic light chain amyloidosis: a 3-dimensional speckle tracking transthoracic echocardiographic study. International Journal of Cardiovascular Imaging, 2019, 35, 845-854.	1.5	8

#	Article	IF	Citations
55	Effects of Patisiran, an RNA Interference Therapeutic, on Cardiac Parameters in Patients With Hereditary Transthyretin-Mediated Amyloidosis. Circulation, 2019, 139, 431-443.	1.6	319
56	Influence of centre expertise on the diagnosis and management of hypertrophic cardiomyopathy: A study from the French register of hypertrophic cardiomyopathy (REMY). International Journal of Cardiology, 2019, 275, 107-113.	1.7	8
57	Myocardial Stiffness Evaluation Using Noninvasive Shear Wave Imaging in Healthy and Hypertrophic Cardiomyopathic Adults. JACC: Cardiovascular Imaging, 2019, 12, 1135-1145.	5.3	108
58	Outcome of patients with cardiac amyloidosis admitted to an intensive care unit for acute heart failure. Archives of Cardiovascular Diseases, 2018, 111, 582-590.	1.6	20
59	Early-phase myocardial uptake intensity of 99mTc-HMDP vs 99mTc-DPD in patients with hereditary transthyretin-related cardiac amyloidosis. Journal of Nuclear Cardiology, 2018, 25, 217-222.	2.1	30
60	Apical sparing pattern of left ventricular myocardial 99mTc-HMDP uptake in patients with transthyretin cardiac amyloidosis. Journal of Nuclear Cardiology, 2018, 25, 2072-2079.	2.1	23
61	A new staging system for cardiac transthyretin amyloidosis. European Heart Journal, 2018, 39, 2799-2806.	2.2	396
62	Left atrial function in patients with light chain amyloidosis: A transthoracic 3D speckle tracking imaging study. Journal of Cardiology, 2018, 71, 419-427.	1.9	33
63	Myocardial iodine concentration measurement using dual-energy computed tomography for the diagnosis of cardiac amyloidosis: a pilot study. European Radiology, 2018, 28, 816-823.	4.5	18
64	Screening, diagnosis and treatment of iron deficiency in chronic heart failure: putting the 2016 European Society of Cardiology heart failure guidelines into clinical practice. European Journal of Heart Failure, 2018, 20, 1664-1672.	7.1	92
65	Development and Validation of a New Tool to Assess Burden of Dietary Sodium Restriction in Patients with Chronic Heart Failure: The BIRD Questionnaire. Nutrients, 2018, 10, 1453.	4.1	2
66	Myocardial native T2 measurement to differentiate light-chain and transthyretin cardiac amyloidosis and assess prognosis. Journal of Cardiovascular Magnetic Resonance, 2018, 20, 58.	3.3	48
67	Tafamidis Treatment for Patients with Transthyretin Amyloid Cardiomyopathy. New England Journal of Medicine, 2018, 379, 1007-1016.	27.0	1,558
68	Author's reply. Journal of Cardiology, 2018, 72, 368.	1.9	0
69	Impact of Pulmonary Hypertension on Outcome in Patients with Severe Aortic Stenosis and Preserved Left Ventricular Ejection Fraction. Clinical Research in Cardiology, 2017, 106, 542-550.	3.3	7
70	How your ears can tell what is hidden in your heart: wild-type transthyretin amyloidosis as potential cause of sensorineural hearing loss inelderly-AmyloDEAFNESS pilot study. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2017, 24, 96-100.	3.0	21
71	Sequential cyclophosphamide-bortezomib-dexamethasone unmasks the harmful cardiac effect of dexamethasone in primary light-chain cardiac amyloidosis. European Journal of Cancer, 2017, 76, 183-187.	2.8	14
72	Prevalence and prognostic impact of left-sided valve thickening in systemic light-chain amyloidosis. Clinical Research in Cardiology, 2017, 106, 331-340.	3.3	29

#	Article	IF	Citations
73	Arterioâ€venous fistula for automated red blood cells exchange in patients with sickle cell disease: Complications and outcomes. American Journal of Hematology, 2017, 92, 136-140.	4.1	18
74	Long-term treatment of transthyretin familial amyloid polyneuropathy with tafamidis: a clinical and neurophysiological study. Journal of Neurology, 2017, 264, 268-276.	3.6	76
75	Myocardial Gene Expression Profiling to Predict and Identify Cardiac Allograft Acute Cellular Rejection: The GET-Study. PLoS ONE, 2016, 11, e0167213.	2.5	14
76	Clinical, ECG and echocardiographic clues to the diagnosis of TTR-related cardiomyopathy. Open Heart, 2016, 3, e000289.	2.3	62
77	Nonbiopsy Diagnosis of Cardiac Transthyretin Amyloidosis. Circulation, 2016, 133, 2404-2412.	1.6	1,335
78	Outcome and incidence of appropriate implantable cardioverter-defibrillator therapy in patients with cardiac amyloidosis. International Journal of Cardiology, 2016, 222, 562-568.	1.7	77
79	Identification of prognostic markers in transthyretin and AL cardiac amyloidosis*. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2016, 23, 194-202.	3.0	54
80	Non-vitamin K antagonist oral anticoagulants and heart failure. Archives of Cardiovascular Diseases, 2016, 109, 641-650.	1.6	12
81	Prevalence, Severity, and Prognostic Value of Sleep Apnea Syndromes in Cardiac Amyloidosis. Sleep, 2016, 39, 1333-1341.	1.1	9
82	Prognostic value of right ventricular systolic function in cardiac amyloidosis. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2016, 23, 158-167.	3.0	77
83	Haematological determinants of cardiac involvement in adults with sickle cell disease. European Heart Journal, 2016, 37, 1158-1167.	2.2	45
84	[18F]-NaF PET/CT imaging in cardiac amyloidosis. Journal of Nuclear Cardiology, 2016, 23, 846-849.	2.1	54
85	Causes and Consequences of Longitudinal LV Dysfunction Assessed by 2D Strain Echocardiography in Cardiac Amyloidosis. JACC: Cardiovascular Imaging, 2016, 9, 126-138.	5.3	150
86	Aortic stenosis and transthyretin cardiac amyloidosis: the chicken or the egg?. European Heart Journal, 2016, 37, 3525-3531.	2.2	108
87	Apneaâ€“hypopnea and desaturations in heart failure with reduced ejection fraction: Are we aiming at the right target?. International Journal of Cardiology, 2016, 203, 1022-1028.	1.7	18
88	Prevalence and clinical phenotype of hereditary transthyretin amyloid cardiomyopathy in patients with increased left ventricular wall thickness. European Heart Journal, 2016, 37, 1826-1834.	2.2	163
89	Arterio-Venous Fistula Is an Applicable Vascular Access for Erythracytapheresis in Patients with Sickle Cell Disease. Blood, 2016, 128, 4856-4856.	1.4	0
90	Development of a Human Model for the Study of Effects of Hypoxia, Exercise, and Sildenafil on Cardiac and Vascular Function in Chronic Heart Failure. Journal of Cardiovascular Pharmacology, 2015, 66, 229-238.	1.9	7

#	Article	IF	Citations
91	Noninvasive detection of cardiac amyloidosis using delayed enhanced MDCT: a pilot study. European Radiology, 2015, 25, 2291-2297.	4.5	19
92	Sleep-disordered breathing in chronic heart failure: development and validation of a clinical screening score. Sleep Medicine, 2015, 16, 1094-1101.	1.6	5
93	Noninvasive detection of cardiac involvement in patients with hereditary transthyretin associated amyloidosis using cardiac magnetic resonance imaging: a prospective study. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2014, 21, 246-255.	3.0	29
94	High prevalence of iron deficiency in patients with acute decompensated heart failure. European Journal of Heart Failure, 2014, 16, 984-991.	7.1	113
95	Diagnosis and treatment of iron deficiency in patients with heart failure: Expert position paper from French cardiologists. Archives of Cardiovascular Diseases, 2014, 107, 563-571.	1.6	27
96	Iron deficiency: an emerging therapeutic target in heart failure. Heart, 2014, 100, 1414-1420.	2.9	95
97	Characterization of untyped cardiac amyloidosis by mass spectrometry in a patient with Gly6Ser transthyretin polymorphism in fatal cardiogenic shock. Archives of Cardiovascular Diseases, 2014, 107, 706-708.	1.6	3
98	Interplay Between Right Ventricular Function and Cardiac Resynchronization Therapy. Journal of the American College of Cardiology, 2013, 61, 2153-2160.	2.8	74
99	Cardiac amyloidosis: Updates in diagnosis and management. Archives of Cardiovascular Diseases, 2013, 106, 528-540.	1.6	181
100	Pulmonary Acceleration Time to Optimize the Timing of Lung Transplant in Cystic Fibrosis. Pulmonary Circulation, 2012, 2, 75-83.	1.7	13
101	Prognostic impact of sleepâ€disordered breathing and its treatment with nocturnal ventilation for chronic heart failure. European Journal of Heart Failure, 2012, 14, 1009-1019.	7.1	120
102	Prevalence of, Associations With, and Prognostic Value of Tricuspid Annular Plane Systolic Excursion (TAPSE) Among Out-Patients Referred for the Evaluation of Heart Failure. Journal of Cardiac Failure, 2012, 18, 216-225.	1.7	135
103	Does the physical examination still have a role in patients with suspected heart failure?. European Journal of Heart Failure, 2011, 13, 1340-1348.	7.1	49
104	Pulmonary Hemodynamic Responses to Inhaled NO in Chronic Heart Failure Depend on PDE5 G(â€1142)T Polymorphism. Pulmonary Circulation, 2011, 1, 377-382.	1.7	10
105	Determinants and prognostic value of pulmonary arterial pressure in patients with chronic heart failure. European Heart Journal, 2010, 31, 2280-2290.	2.2	155
106	Comparison of four right ventricular systolic echocardiographic parameters to predict adverse outcomes in chronic heart failure. European Journal of Heart Failure, 2009, 11, 818-824.	7.1	69
107	Prevalence of sleep-disordered breathing in a 316-patient French cohort of stable congestive heart failure. Archives of Cardiovascular Diseases, 2009, 102, 169-175.	1.6	72
108	Pharmacokinetic and pharmacodynamic interactions between metoprolol and dronedarone in extensive and poor CYP2D6 metabolizers healthy subjects. Fundamental and Clinical Pharmacology, 2004, 18, 113-123.	1.9	57

#	Article	IF	Citations
109	Natural course and determinants of short-term kidney function decline in hereditary transthyretin amyloidosis: a French observational study. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 0, , 1-11.	3.0	1